Abuse-Deterrent Opioids: FDA Regulatory Options Aired At Meeting
This article was originally published in Pharmaceutical Approvals Monthly
Brand industry favors two- to three-year period for withdrawal or reformulation of products without abuse-deterrent features, while generic industry calls for expedited review pathway. Purdue and Zogenix agree to waive three-year market exclusivity for their respective hydrocodone products.
You may also be interested in...
Former FDA Principal Deputy Commissioner Joshua Sharfstein suggests FDA create a pathway for development of new products for simultaneous treatment of chronic pain and opioid disorder.
FDA draft guidance says there is no clear epidemiologic strategy for gathering the data to demonstrate that has reduced abuse; the agency outlines four possible kinds of abuse deterrence claims, three of which can be obtained through pre-market studies.
Delaware district judge rules against AstraZeneca’s claim the IRA violates its due process rights, echoing findings made by Ohio district judge in Chamber of Commerce’s suit. Only other IRA ruling to date dismissed PhRMA’s complaint on procedural grounds without addressing the merits.